Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Stella Diagnostics Inc. is a molecular diagnostics firm primarily focused on advancing patient care strategies for individuals afflicted with severe esophageal disorders. The company's specialized clinical tests furnish physicians with crucial information regarding the molecular makeup of a patient's tissue, enabling them to ascertain if the disease is static, deteriorating, or undergoing malignant transformation. Additionally, Stella Diagnostics is engaged in the development of innovative diagnostic tools intended to provide healthcare professionals with enhanced molecular insights compared to conventional screening methods. The organization rebranded from its previous identity, JMP Properties, Inc., to Stella Diagnostics, Inc. in April 2021 and is based in Salt Lake City, Utah.
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is underpriced on P/FCF.